Focused On-demand Library for Cysteine and glycine-rich protein 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P50461

UPID:

CSRP3_HUMAN

Alternative names:

Cardiac LIM protein; Cysteine-rich protein 3; LIM domain protein, cardiac; Muscle LIM protein

Alternative UPACC:

P50461; Q9P131; S4S7M7

Background:

Cysteine and glycine-rich protein 3, also known as Cardiac LIM protein, plays a pivotal role in myogenesis and cardiomyocyte structure. It acts as a cofactor for myogenic transcription factors, enhances DNA-binding activity, and is crucial in cytosolic structure organization in cardiomyocytes. It also interacts with actin filaments, promoting their assembly and protecting them from depolymerization.

Therapeutic significance:

Given its involvement in dilated cardiomyopathy and familial hypertrophic cardiomyopathy, understanding the role of Cysteine and glycine-rich protein 3 could lead to novel therapeutic strategies for these heart disorders. Its function in myogenesis and cardiomyocyte integrity suggests potential targets for drug development.